Eicosanoid pathway on host resistance and inflammation during Mycobacterium tuberculosis infection is comprised by...

The functions of eicosanoids, a family of potent biologically active lipid mediators, are not restricted to inflammatory responses and they also act as mediators of the pathogenesis process. However, the role of eicosanoids in tuberculosis remains controversial. To investigate the specific role of LTB₄ in Mycobacterium tuberculosis (Mtb) infection, we used 5-lipoxygenase-deficient (5-LO^-/-) mice and WT (sv129) mice inoculated intranasally with LTB₄ (encapsulated in PLGA microspheres). We showed that deficiency of the 5-LO pathway was related to resistance to Mtb infection. LTB₄ inoculation increased susceptibility to Mtb in 5-LO^-/- mice but not in WT mice, resulting in worsening of lung inflammation and tissue damage. In infected WT mice, most supplementary LTB₄ was metabolized to the inactive form 12-oxo-LTB₄ in the lung. A high amount of PGE₂ was detected during Mtb infection, and pharmacological inhibition of COX-2 induced a significant reduction of bacterial load and an improved innate immune response in the lungs, independently of baseline LTB₄ levels. COX-2 inhibition with celecoxib significantly reduced PGE₂ levels, enhanced IFN-γ production and NO release, and increased macrophage phagocytosis of Mtb. The results suggest that a balance between PGE₂/LTB₄ is essential in the pathogenesis process of tuberculosis to prevent severe inflammation. Moreover, optimal levels of PGE₂ are required to induce an effective innate response in the early phase of Mtb infection. Thus, pharmacological modulation of eicosanoid production may provide an important host-directed therapy in tuberculosis.